1. Generics Bulletin
  2. >>Archive

Mylan seeks to make virtue from complexity of pipeline

In building an extensive pipeline of complex products that includes biosimilars, small-molecule injectables and respiratory inhalers, Mylan believes it will deliver durable cash flows and a platform for growth. Aidan Fry examines the company’s plans.

As the generics industry struggles to come to terms with a consolidated US customer base applying severe pricing pressure, Mylan is keen to stress that it is “not just a US-based generics company”. Rather, the group used a recent investors’ day to highlight its broad geographic footprint across more than 160 countries and its diverse portfolio of generics, prescription brands and OTC products, delivered through a wide range of distribution channels.

“We have built tremendous diversity into our commercial, operational and scientific platforms,” insisted chief executive officer Heather Bresch. “The result...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

Adalvo Eyes Early Generic Semaglutide Access In Europe As Data Exclusivity Lifts

 
• By Dean Rudge

B2B player Adalvo said its generic semaglutide dossier “is already prepared and has been submitted and approved in several markets worldwide,” as it announced plans to file an EU decentralized procedure application early next year.

Dutch Ustekinumab Ruling Diverts From UK As Samsung Bioepis Challenge Fails

 
• By Dean Rudge

Samsung Bioepis will not be able to add an ulcerative colitis indication to its ustekinumab biosimilar in the Netherlands for now, after failing to have a key patent revoked.

Indapamide Breaks The Scale With A 1,000%+ UK Rise In August

 
• By Dave Wallace

A massive 1,115% average price increase was seen for indapamide 2.5mg tablets in the UK in August.